Fibrosis and progression of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1812, Issue 10, 2011, Pages 1327-1336

  Norman, Jill ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Chronic kidney disease; Epithelial fibroblast interactions; Extracellular matrix; Fibroblasts; Fibrosis; Myofibroblasts

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BONE MORPHOGENETIC PROTEIN; COLLAGEN; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC AMP; DOUBLE STRANDED RNA; ELASTIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; LAMININ; MATRIX METALLOPROTEINASE 14; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; OSTEOPONTIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; POLYCYSTIN 1; POLYCYSTIN 2; PROTEOGLYCAN; SCATTER FACTOR; STRESS ACTIVATED PROTEIN KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

APOPTOSIS; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE; CELL DIVISION; CELL INTERACTION; CELL POLARITY; CELL PROLIFERATION; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DNA METHYLATION; DNA POLYMORPHISM; DNA SEQUENCE; EPIGENETICS; EXTRACELLULAR MATRIX; FIBROBLAST; FOCAL ADHESION; GENE EXPRESSION; GENE MUTATION; HISTONE MODIFICATION; HUMAN; KIDNEY FAILURE; KIDNEY FIBROSIS; KIDNEY POLYCYSTIC DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL REPLACEMENT THERAPY; REVIEW; SECRETION; UPREGULATION;

ANIMALS; CELL DIFFERENTIATION; CILIA; DISEASE PROGRESSION; EPIGENESIS, GENETIC; EXTRACELLULAR MATRIX; FIBROSIS; GROWTH SUBSTANCES; HUMANS; INFLAMMATION; KIDNEY; MICE; MICRORNAS; MODELS, BIOLOGICAL; MYOFIBROBLASTS; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS;

EID: 80052268964     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2011.06.012     Document Type: Review

References (126)

1. Wilson P.D. Molecular and cellular aspects of polycystic kidney disease. N. Engl. J. Med. 2004, 350:151-164.
2. Wilson P.D., Norman J.T., Kuo N., Burrow C.R. Abnormalities in extracellular matrix regulation in autosomal dominant polycystic kidney disease (ADPKD). Contrib. Nephrol. 1996, 118:126-134.
3. Hanaoka K., Guggino W.B. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J. Am. Soc. Nephrol. 2000, 11:1179-1187.
4. Richards W.G., Sweeney W.E., Yoder B.K., Wilkinson J.E., Woychik R.P., Avner E.D. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J. Clin. Invest. 1998, 101:935-939.
5. Du J., Wilson P.D. Abnormal polarized location of EGF receptors: a mechanism for autocrine stimulation of epithelial proliferation in cyst formation in human polycystic kidney disease. Am. J. Physiol. 1995, 269:C498-C.
6. Sutters M., Yamaguchi T., Maser R.L., et al. Polycystin-1 transforms the cAMP growth-responsive phenotype of M-1 cells. Kidney Int. 2001, 60:484-494.
7. Wilson P.D. Pathogenesis of polycystic kidney disease: altered cellular function. Polycystic Kidney Disease, Oxford Monographs on Clinical Nephrology 1996, 125-163. M. Watson, V. Torres (Eds.).
8. Baboolal K., Ravine D., Daniels J., et al. Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in PKD1 adult polycystic kidney disease. Kidney Int. 1997, 52:607-613.
9. Rossetti S., Burton S., Stromecki L., et al. The position of the polycystic kidney disease 1 (PKD1) gene mutation correlates with the severity of renal disease. J. Am. Soc. Nephrol. 2002, 13:1230-1237.
10. Brook-Carter P.T., Peral B., Ward C.J., et al. Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease - a contiguous gene syndrome. Nat. Genet. 1994, 8:328-332.
11. Lantinga-van Leeuwen I.S., Dauwerse J.G., Baelde H.J., et al. Lowering Pkd expression is sufficient to cause polycystic kidney disease. Hum. Mol. Genet. 2004, 13:3069-3077.
12. Wang E., Hsieh-Li H.M., Chiou Y.Y., Chien Y.L., Ho H.H., Chin H.J., Wang C.K.L., Liang S.L., Jiang S.T. Progressive renal distortion by multiple cysts in transgenic mice expressing artificial microRNAs against Pkd1. J. Pathol. 2010, 222:238-248.
13. Harris P.C., Bae K.T., Rossetti S., Torres V.E., Grantham J.J., Chapman A.B., Guay-Woodford L.M., King B.F., Wetzel L.H., Baumgarten D.A., Kennedy P.J., Consigal M., Klahr S., Bennett W.M., Meyer C.M., Zhang Q.J., Thompson P.A., Zhu F., Miller J.P. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J. Am. Soc. Nephrol. 2006, 17:3013-3019.
14. Schnaper H.W., Kopp J.B. Renal fibrosis. Front. Biosci. 2003, 8:e68-e86.
15. Eddy A.A. Progression in chronic kidney disease. Adv. Chronic Kidney Dis. 2005, 12:353-365.
16. Fogo A.B. Mechanisms of progression of chronic kidney disease. Pediatr. Nephrol. 2007, 22:2011-2022.
17. Boor P., Sebokova K., Ostendorf T., Floege J. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant. 2007, 22:3391-33407.
18. Picard N., Baum O., Vogetseder A., Kaissling B., Le Hir M. Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem. Cell Biol. 2008, 130:141-155.
19. Qi W., Chen X., Poronnik P., Pollock C.A. The renal cortical fibroblast in renal tubulointerstitial fibrosis. Int. J. Biochem. Cell Biol. 2006, 38:1-5.
20. Iwano M., Pleito D., Dannoff T.M., Xue C., Okada H., Neilson E.G. Evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest. 2002, 110:341-350.
21. Liu Y. Epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J. Am. Soc. Nephrol. 2004, 15:1-12.
22. Liu Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 2010, 21:212-222.
23. Zeisberg M., Duffield J. Resolved; Epithelial-mesenchymal transistion produces fibroblasts in the kidney. J. Am. Soc. Nephrol. 2010, 21:1247-1253.
24. Humphreys B.D., Lin S.-L., Kobayashi A., Hudson T.E., Towlin B.T., Bonventre J.V., Valerius M.T., McMahon A.P., Duffield J.S. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 2010, 176:85-97.
25. Zeisberg E.M., Potenta S.E., Sugimoto H., Zeisberg M., Kalluri R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 2008, 17:2282-2287.
26. Li J., Qu X., Bertram J.F. Endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 2009, 175:1380-1388.
27. Fine L.G., Norman J.T. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008, 74:867-872.
28. Verderio E.A., Johnson T., Griffin M. Tissue transglutaminase in normal and abnormal wound healing: review article. Amino Acids 2004, 26:387-404.
29. Norman J., Fine L.G. Progressive renal disease: fibroblasts, extracellular matrix and integrins. Exp. Nephrol. 1999, 7:167-177.
30. Cheng S., Lovett D.H. Gelatinase A (MMP-2) is necessary and sufficient for renal tubular epithelial-mesenchymal transformation. Am. J. Pathol. 2003, 162:1937-1949.
31. Kim H., Oda T., Lopez-Guisa J., Wing D., Edwards D.R., Soloway P., et al. TIMP-1 deficiency does not attenuate interstitial fibrosis in obstructive nephropathy. J. Am. Soc. Nephrol. 2001, 12:736-748.
32. Kassiri Z., Oudit G.Y., Kanadalam V., Awad A., Wang X., Ziou X., et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 2009, 20:1223-1235.
33. Brew K., Nagase H. The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity. Biochim. Biophys. Acta 2010, 1477:55-71.
34. Eddy A.E. Serine proteases, inhibitors and receptors in renal fibrosis. Thromb. Haemost. 2009, 101:656-664.
35. Boor P., Floege J. Growth factors in renal fibrosis. Clin. Exp. Pharmacol. Physiol. 2011, 38:391-400.
36. Vernon M.A., Mylonas K.J., Hughes J. Macrophages and renal fibrosis. Semin. Nephrol. 2010, 30:302-317.
37. Wynn T.A., Barron L. Macrophages: master regulators of inflammation and fibrosis. Semin. Liver Dis. 2010, 30:245-257.
38. Liu Y. Renal fibrosis: new insights into pathogenesis and therapeutics. Kidney Int. 2006, 69:213-217.
39. Zhang Y.E. Non-Smad pathways in TGF-β signaling. Cell Res. 2009, 19:128-139.
40. Martínez-Salgado C., Rodríguez-Peña A.B., López-Novoa J.M. Involvement of small Ras GTPases and their effectors in chronic renal disease. Cell. Mol. Life Sci. 2008, 65:477-492.
41. Li Y., Tan X., Dai C., Stolz D.B., Wang D., Liu Y. Inhibition of integrin-linked kinase attentuate renal interstitial fibrosis. J. Am. Soc. Nephrol. 2009, 20:1907-1908.
42. Surendran K., McCaul S.P., Simon T.C. A role of Wnt-4 in renal fibrosis. Am. J. Physiol. 2002, 282:F431-F441.
43. Bechtel W., McGoohan S., Zeisberg E.M., Müller G.A., Kalbacher H., Salant D.J., Müller C.A., Kalluri R., Zeisberg M. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat. Med. 2010, 16:544-551.
44. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:213-233.
45. Vasudevan S., Tong Y., Steitz J.A. Switching from repression to activation: microRNAs can up-regulate translation. Science 2007, 318:1931-1934.
46. Jiang X., Tsitsiou E., Herrick S.E., Lindsay M.A. MicroRNAs and the regulation of fibrosis. FEBS J. 2010, 277:2015-2021.
47. Sun Y., Koo S., Whie N., Peralta E., Esau C., Dean N.M., Perera R.J. Development of a micro-array to detect human and mouse microRNAs and characterization of expression in human organs. Nucleic Acids Res. 2004, 32:e188.
48. Tian Z., Greene A.S., Pietrusz J.L., Matus I.R., Liang M. MicroRNA-target pairs in the rat kidney identified by microRNA microarray, proteomic and bioinformatic analysis. Genome Res. 2008, 18:404-411.
49. Chung A.C.K., Huang X.R., Meng X., Lan H.Y. miR-192 mediates TGF-β/Smad3 driven renal fibrosis. J. Am. Soc. Nephrol. 2010, 21:1317-1325.
50. Kato M., Zhang J., Wang M., Lanting L., Yuan H., Rossi J.J., Natarajan R. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of E-box repressors. Proc. Natl Acad. Sci. U. S. A. 2007, 104:3432-3437.
51. Krupa A., Jenkins R., Luo D.D., Lewis A., Phillips A., Fraser D. Loss of microRNA-192 promotes fibrogenesis in diabetic nephropathy. J. Am. Soc. Nephrol. 2010, 21:438-477.
52. Kato M., Putta S., Wang M., Yuan H., Lanting L., Nair I., Gunn A., Nakagawa Y., Shimano H., Todorov I., et al. TGF-beta activates Akt kinase through a micro-RNA-dependent amplifying circuit targeting PTEN. Nat. Cell Biol. 2009, 11:881-889.
53. Wang Q., Wang Y., Minto A.W., Wang J., Shi Q., Li X., Quigg R.J. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 2008, 22:4126-4135.
54. Rossetti S., Chauveau D., et al. Association of mutation position in polycystic kidney disease 1 (PKD1) gene and development of a vascular phenotype. Lancet 2003, 361:2196-2201.
55. Zeier M., Fehrenbach P., et al. Renal histology in polycystic kidney disease with incipient and advanced renal failure. Kidney Int. 1992, 42:1259-1265.
56. Antiga L., Piccinelli M., Fasolini G., Ene-Iordache B., Ondei P., Bruno S., Remuzzi G., Remuzzi A. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin. J. Am. Soc. Nephrol. 2006, 1:754-770.
57. Wilson P.D., Falkenstein D. The pathology of human renal cystic disease. Current Topics in Pathology 1995, Vol. 31:1-50. Springer-Verlag. S. Dodd (Ed.).
58. Wilson P.D., Goilav B. Cystic disease of the kidney. Annu. Rev. Pathol. 2006, 2:341-368.
59. Song X., Di Giovanni V., He N., Wang K., Ingram A., Rosenblum N.D., Pei Y. Systems biology of autosomal dominant polycystic kidney disease (ADPKD): computational integration of gene expression pathways and integrated networks. Hum. Mol. Genet. 2009, 18:2328-2343.
60. Wilson P.D., Hreniuk D., Gabow P. Relationship between abnormal extracellular matrix and excessive growth of human adult polycystic kidney disease epithelia. J. Cell. Physiol. 1992, 150:360-369.
61. Wilson P.D., Sherwood A.C. Tubulocystic epithelium in the cell biology and structure of the tubulo-interstitum in health and disease. Kidney Int. 1991, 39:450-463.
62. Wilson P.D., Geng L., Li X., Burrow C.R. The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia. Lab. Invest. 1999, 79:1311-1323.
63. Wilson P.D., Burrow C.R. Cystic diseases of the kidney: role of adhesion molecules in normal and abnormal tubulogenesis. Exp. Nephrol. Special Issues 1999, 7:114-124. M. Goligorsky (Ed.).
64. Guay-Woodford L.M. Murine models of polycystic kidney disease: molecular and therapeutic insights. Am. J. Physiol. 2003, 285:F1034-F1049.
65. Wilson P.D. Mouse models of polycystic kidney disease. Curr. Top. Dev. Biol. 2008, 84:311-350.
66. Hassane S., Leonhard W.N., van der Wal A., Hawinkels L.J.A.C., Lantinga-van Leeuwen I.S., ten Dijke P., Breuning M.H., de Heer E., Peters D.J.M. Elevated TGFβ-Smad signalling in experimental Pkd1 modles and human patients with polycystic kidney disease. J. Pathol. 2010, 222:21-31.
67. Mangos S., Lam P-Y., Zhao A., Liu Y., Mudumana S., Vasilyev A., Liu A., Drummond I.A. The ADPKD genes pkd1a/b and pkd2 regulate extracellular matrix formation. Dis. Model. Mech. 2010, 3:354-365.
68. Catania J.M., Chen G., Parrish A.R. Role of matrix metalloproteinases in renal pathophysiologies. Am. J. Physiol. Renal Physiol. 2007, 292:F905-F911.
69. Schaefer L., Han X., Gretz N., Hafner C., Meier K., Matzkies F., Schaefer R.M. Tubular gelatinase A (MMP-2) and its tissue inhibitors in polycystic kidney disease in the Han:SPRD rat. Kidney Int. 1996, 49:75-81.
70. Obermuller N., Morente N., Kranzlin B., Gretz N., Witzgall R. A possible role for the metalloproteinases in renal cyst development. Am. J. Physiol. Renal Physiol. 2001, 280:F540-F550.
71. Rankin C.A., Suzuki K., Itoh Y., Zeimer D.M., Grantham J.J., Calvet J.P., Nagase H. Matrix metalloproteinases and TIMPs in cultured C57BL/6J-cpk kidney tubules. Kidney Int. 1996, 50:835-844.
72. Nakamura T., Ushiyama C., Suzuki S., Ebihara I., Shimada N., Koide H. Elevation of serum levels of metalloproteinase-1, tissue inhibitor of metalloproteinase-1 and type IV collagen, and plasma levels of metalloproteinase-9 in polycystic kidney disease. Am. J. Nephrol. 2000, 20:32-36.
73. Kistler A.D., Mischak H., Poster D., Dakna M., Wuethrich R.P., Serra A.L. Identification of unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2009, 76:86-96.
74. Geiger B., Bershadsky A., Pankov R., Yamada K.M. Transmembrane cross-talk between the extracellular matrix-cytoskeleton cross-talk. Nat. Rev. Mol. Cell Biol. 2001, 2:793-805.
75. Ehrhardt A., Ehrhardt G.R., Guo X., Schrader J.W. Ras and relatives-job sharing and networking keep an old family together. Exp. Hematol. 2002, 30:1089-1106.
76. Wozniak M., Modzelewska K., Kwong L., Keely P.J. Focal adhesion regulation of cell behaviour. Biochim. Biophys. Acta 2004, 1692:103-119.
77. Zeltner R., Hilgers K.F., Schmeider R.E., Porst M., Schulze B.D., Hartner A. A promoter polymorphism of the alpha 8 integrin and the progression of autosomal-dominant polycystic kidney disease. Nephron Clin. Pract. 2008, 108:c169-c175.
78. Wallace D.P., Quante M.T., Reif G.A., Nivens E., Ahmed F., Hempson S.J., Blanco G., Yamaguchi T. Periostin induces proliferation of human autosomal dominant polycystic kidney cells through alphaV-integrin receptor. Am. J. Physiol. Renal Physiol. 2008, 295:F1463-F1471.
79. Joly D., Morel V., Hummel A., Ruello A., Nusbaum P., Patey N., Noel L.H., Rousselle P., Knebelmann B. Beta4 integrin and laminin5 are aberrantly expressed in polycystic kidney disease: role in increased cell adhesion and migration. Am. J. Pathol. 2001, 163:1791-1800.
80. Schieren G., Rumberger B., Klein M., Kreutz C., Wilpert J., Geyer M., Faller D., Timmer J., Quack I., Rump L.C., Wlaz G., Donauer J. Gene profiling of polycystic kidneys. Nephrol. Dial. Transplant. 2006, 21:1816-1824.
81. Kuo N.T., Norman J.T., Wilson P.D. Acidic FGF regulation of hyperproliferation of fibroblasts in human autosomal dominant polycystic kidney disease. Biochem. Mol. Med. 1997, 61:178-191.
82. Castella L.F., Gabbiani G., McCulloch C.A., Hinz B. Regulation of myofibroblast activities: calcium pulls some of the strings behind the scene. Exp. Cell Res. 2010, 316:2390-2401.
83. Togawa H., Nakanishi K., Mukaiyama H., Hama T., Shimu Y., Sako M., Miyajima M., Nozu K., Nashii K., Nagao S., Takahashi H., Iijima K., Yoshikawa N. Epithelial to mesenchymal transition in cyst-lining epithelial cells in as orthologous PCK rat model of autosomal recessive polycystic kidney disease. Am. J. Physiol. 2011, 300:F511-F520.
84. Polgar K., Burrow C.R., Hyink D., Fernandez H., Thornton K., Li X., Gusella G.L., Wilson P.D. Disruption of polycystin-1 function interferes with branching morphogenesis of the ureteric bud in developing mouse kidneys. Dev. Biol. 2005, 286:16-30.
85. Chapin H.C., Caplan M.J. The cell biology of polycystic kidney disease. J. Cell Biol. 2010, 191:701-710.
86. Torres V.E., Harris P.C. Autosomal dominant polycystic kidney disease: the last 3years. Kidney Int. 2009, 76:149-168.
87. Wilson P.D. Polycystic kidney disease: new understanding in the pathogenesis. Int. J. Biochem. Cell Biol. 2004, 36:1868-1873.
88. Low S.H., Vasnath S., Larson C.H., et al. Poycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev. Cell 2006, 10:57-69.
89. Lal M., Song X., Pluznick J.L., et al. Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum. Mol. Genet. 2008, 17:3105-3117.
90. Griffin M.D., Torres V.E., Grande J.P., Kumar R. Vascular expression of polycystin. J. Am. Soc. Nephrol. 1997, 8:616-626.
91. Gallagher A.R., Germino G.G., Somlo S. Molecular advances in autosomal dominant polycystic kidney disease. Adv. Chronic Kidney Dis. 2010, 17:118-130.
92. Boulter C., Mulroy S., et al. Cardiovascular, skeletal, and renal defects in mice with a targeted disruption of the Pkd1 gene. Proc. Natl Acad. Sci. U. S. A. 2001, 98:12174-12179.
93. Kim K., Drummond I., et al. Polycystin 1 is required for the structural integrity of blood vessels. Proc. Natl Acad. Sci. U. S. A. 2000, 97:1731-1736.
94. Bello-Reuss E., Holubec K., Rajaraman S. Angiogenesis in autosomal dominant polycystic kidney disease. Kidney Int. 2001, 60:37-45.
95. Chapman A.B., Schrier R.W. Pathogenesis of hypertension in autosomal dominant polycystic kidney disease. Semin. Nephrol. 1991, 11:653-660.
96. Schrier R.W., McFann K.K., et al. Epidemiological study of kidney survival in autosomal dominant polycystic kidney disease. Kidney Int. 2003, 63:678-685.
97. Kocaman O., Oflaz H., et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 2003, 43:854-860.
98. Ong A.C., Newby L.J., et al. Expression and cellular localisation of renal endothelin-1 and endothelin receptor subtypes in autosomal-dominant polycystic kidney disease. Nephron Exp. Nephrol. 2003, 93:e80.
99. Persu A., Stoenoiu M.S., et al. Modifier effect of eNOS in autosomal dominant polycystic kidney disease. Hum. Mol. Genet. 2002, 11:229-241.
100. Wang D., Iversen J., et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int. 2003, 64:1381-1388.
101. Qian Q., Hunter L.W., et al. Pkd2 haploinsufficiency alters intracellular calcium regulation in vascular smooth muscle cells. Hum. Mol. Genet. 2002, 12:1875-1880.
102. Kip S.N., Hunter L.W., et al. [Ca2+]i reduction increases cellular proliferation and apoptosis in vascular smooth muscle cells: relevance to the ADPKD phenotype. Circ. Res. 2005, 96:873-880.
103. Bernhardt W.M., Weisener M.S., Weldemann A., Schmitt R., Weigchert W., Lechler P., Campean V., Ong A.C.M., Wilam C., Gretz N., Eckardt K.-U. Involvement of hypoxia-inducible transcription factors in polycystic kidney disease. Am. J. Pathol. 2007, 170:830-842.
104. Lee S.O., Masyuk T., Splinter P., Banales J.M., Masyuk A., Stroope A., Larusso N. MicroRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects cystogenesis in a rat model of polycystic kidney disease. J. Clin. Invest. 2008, 118:3714-3724.
105. Satir P., Christensen S.T. Overview of structure and function of mammalian cilia. Annu. Rev. Physiol. 2007, 69:377-400.
106. Veland I., Awan A., Pedersen L., Yoder B.K., Christensen S.T. Primary cilia and signaling pathways in mammalian development, health and disease. Nephron Physiol. 2009, 111:39-53.
107. Berbari N.F., O'Connor A.K., Haycraft C.J., Yoder B.K. The primary cilium as a complex signalling centre. Curr. Biol. 2009, 19:R526-R535.
108. Schnieder L., Cammer M., Lehman J., Neilsen S.K., Guerra C.F., Veland I.R., Stock C., Hoffman E.K., Yoder B.K., Schwab A., Satir P., Christensen S.T. Direction cell migration and chemotaxis in wound healing response to PDGF-AA are coordinated by the primary cilium in fibroblasts. Cell. Physiol. Biochem. 2010, 25:279-292.
109. Nishio S., Hatano M., Nagata M., Horie S., Koike T., Tokuhisa T., Mochizuki T. Pkd1 regulates immortalized proliferation of renal tubular epithelial cells through p53 induction and JNK activation. J. Clin. Invest. 2005, 115:910-918.
110. Boca M., D'Amamto L., Distefano G., Polishchuk R.S., Germinao G.G., Boletta A. Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase dependent cytoskeletal rearrangements and GSK3beta-dependent cell-cell mechanical adhesion. Mol. Cell. Biol. 2007, 18:4050-4061.
111. Wu J., Du H., Wang X., Mei C., Sieck G.C., Qian Q. Characterisation of primary cilia in human airway smooth muscle cells. Chest 2009, 136:561-570.
112. Lu C.J., Du H., Wu J., Jansen D.A., Jordan K.L., Xu N., Sieck G.C., Qian Q. Non-random distribution and sensory functions of primary cilia in vascular smooth muscle cells. Kidney Blood Press. Res. 2008, 31:171-184.
113. Ramasubbu K., Gretz N., Bachmann S. Increased epithelial cell proliferation and abnormal matrix in rat polycystic kidney disease. J. Am. Soc. Nephrol. 1998, 9:937-945.
114. Chang M.Y., Parker E., Ibrahim S., Shortland J.R., El Nahas M., Haylor J.L., Ong A.C.M. Haploinsufficiency of Pkd2 is associated with increased tubular cell proliferation and interstitial fibrosis in two murine Pkd2 models. Nephrol. Dial. Transplant. 2006, 21:2078-2084.
115. Norman J.T., Gatti L., Wilson P.D., Lewis M. Matrix metalloproteinases and tissue inhibitor of matrix metalloproteinases expression by tubular epithelia and interstitial fibroblasts in the normal kidney and in fibrosis. Exp. Nephrol. 1995, 3:88-89.
116. Saxen L. What is needed for kidney differentiation and how do we find it?. Int. J. Dev. Biol. 1999, 43:377-380.
117. Dressler G. The cellular basis of kidney development. Annu. Rev. Cell Dev. Biol. 2006, 22:509-529.
118. Rodemann H.P., Müller G., Knecht A., Norman J.T., Fine L.G. Fibroblasts of the rabbit kidney in culture. I. Characterization of growth properties and identification of cell-specific markers. Am. J. Physiol. 1991, 261:F283-F291.
119. Knecht A., Fine L.G., Rodemann H.P., Müller G., Kleinman K.S., Woo D., Norman J.T. Fibroblasts of the rabbit kidney in culture. II. Paracrine stimulation of papillary fibroblasts by PDGF. Am. J. Physiol. 1991, 261:F292-F299.
120. Lewis M., Fine L.G., Norman J.T. Pexicrine effects of basement membrane components on paracrine signalling by renal tubular cells. Kidney Int. 1996, 49:48-58.
121. Johnson D.W., Saunders H.J., Baxter R.C., Field M.J., Pollock C.A. Paracrine stimulation of human renal fibroblasts by proximal tubule cells. Kidney Int. 1998, 54:747-757.
122. Zvaifler N.J. Relevance of the stroma and epithelial-mesenchymal transition (EMT) for the rheumatic diseases. Arthritis Res. Ther. 2006, 8:210-221.
123. Roitbak T., Ward C.J., Harris P.C., Bacallao R., Ness S.A., Wandinger-Ness A. A polycystin-1 multiprotein complex is disrupted in polycystic kidney disease cells. Mol. Biol. Cell 2004, 15:1334-1346.
124. Vilayur Y., Harris D.C. Emerging therapies for chronic kidney disease: what is their role?. Nat. Rev. Nephrol. 2009, 5:375-383.
125. Albaqumi M., Srivastava S., Li Z., Zhdnova O., Wulff H., Itani O., Wallace D.P., Skolnik E.Y. KCa3.1 potassium channels are critical for cAMP-dependent chloride secretion and cyst growth in autosomal-dominant polycystic kidney disease. Kidney Int. 2008, 74:740-749.
126. Grgic I., Kiss E., Kaistha B.P., Busch C., Kloss M., Sautter J., Müller A., Kaistha A., Schmidt C., Raman G., Wulff H., Strutz F., Gröne H.J., Köhler R., Hoyer J. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc. Natl Acad. Sci. U. S. A. 2009, 106:14518-14523.